Type 2 Diabetes Mellitus (T2DM)
Conditions
Brief summary
This study is a randomized, open-label, single dose, crossover study to evaluate the food effect of CKD-383 in healthy volunteers
Detailed description
To 30 healthy subjects, following treatments are administered dosing in each period and wash-out period is 7 days
Interventions
DRUGCKD-383
QD, PO
Sponsors
Bumin Hospital
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adults volunteers between the ages of 19 years to 55 years. 2. Individuals who had 18.0 kg/m2 ≤ Body Mass Index(BMI) \< 30.0 kg/m2 and total body weight ≥ 50 kg (woman total body weight ≥ 45 kg) BMI = Weight(kg)/ Height(m)2 3. Following vital signs results at screening * Systolic blood pressure: 90 mmHg to 150 mmHg * Diastolic blood pressure: 50 mmHg to 100 mmHg 4. Individuals who is determined by investigators to be suitable as a test subject as a result of the examination conducted at the time of screening 5. Individuals who agreed proper contraception during the study and did consent to not donation of sperm 7 days after the last dose of study drug 6. Individuals who signed an informed consent form after being fully informed of the study prior to participation, including the objective and content
Exclusion criteria
1. Clinically significant biliary tract (such as hepatic dysfunction, liver failure, etc.), kidney (stage 3b), and severe renal impairment (eGFR \<60 mL/min/1.73 m2), nervous system, immune system, respiratory system (such as pulmonary infarction, severe pulmonary dysfunction and other hypoxemia prone conditions, respiratory failure, etc.), urinary system, digestive system (such as diarrhea and vomiting), endocrine system, blood and tumor, cardiovascular system (acute myocardial infarction, shock, acute and unstable heart failure, decompensated heart failure, severe heart failure, or those with a history of heart failure (such as New York Heart Association(NYHA) Classification 3 and 4 heart failure) 2. Acute or chronic metabolic acid patients with type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without a coma, and diabetic ketoacidosis patients 3. Patients with diabetic comas and ex-marriage 4. Individuals who have an acute condition that can change his or her renal function, such as dehydration, before and after surgery, severe infection, severe traumatic systemic disorder, cardiovascular collapse (shock), sepsis, etc 5. Patients undergoing intravenous examination of radiodine contrast agents (e.g., intravenous urinary tract, intravenous cholangiography, angiography, computed tomography with contrast agents, etc.) 6. Patients with malnutrition, starvation, weakness, pituitary dysfunction or adrenal insufficiency 7. Individuals who have a history of gastrointestinal diseases (Cron's disease, ulcerative colitis, etc.) or surgery (excluding simple appendectomy or hernia surgery) that may affect the absorption of drugs 8. Individuals who have a history of clinically significant hypersensitivity reactions to the main components and components of clinical trial drugs and other drugs (viguanide drugs, thiazolidinedione drugs, etc.) 9. Individuals who have a history of drug abuse within one year of screening or who has tested positive for a urine drug test 10. Pregnant women, women who may be pregnant, nursing women 11. Those who consumed excessive smoking or caffeine or alcohol within one month prior to the first administration of clinical trial drugs (caffeine: \>5 cups/day, alcohol: male: \>21 cups/week, female: \>14 cups/week, tobacco: \>20 cigarettes/day), or who cannot stop smoking, caffeine and alcohol consumption during each hospitalization period 12. If the investigators determines that the drug may affect the clinical trial or the safety of the subject by administering prescription drugs or herbal medicines within 14 days prior to the first administration of investigational product or general medicines including health foods and vitamin preparations within 7 days 13. Individuals who have taken a drug metabolase-inducing and inhibiting drug, such as barbitals, within 30 days prior to the first administration of investigational product 14. Individuals who had been administered investigational product from other clinical study(include bioequivalence study) within the 6 months prior to the first administration of investigational drugs 15. Individuals who donated whole blood within the 8 weeks, or blood components within 2 weeks or had a blood transfusion within 30 days prior to the first administration of investigational drugs 16. Those who are deemed insufficient to participate in this clinical study by investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUCt of CKD-383 | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hours | Area under the CKD-383 concentration in blood-time curve from 0 to t |
| Cmax of CKD-383 | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hours | The maximum CKD-383 concentration in blood sampling time t |
Countries
South Korea
Outcome results
None listed